Compare SRI & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SRI | RNA |
|---|---|---|
| Founded | 1965 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 205.4M | 222.5M |
| IPO Year | 1997 | 2025 |
| Metric | SRI | RNA |
|---|---|---|
| Price | $7.22 | $10.51 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 20 |
| Target Price | $16.00 | ★ $69.26 |
| AVG Volume (30 Days) | 104.5K | ★ 208.8K |
| Earning Date | 05-01-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $824,444,000.00 | N/A |
| Revenue This Year | N/A | $88.12 |
| Revenue Next Year | $4.73 | $18.11 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 18.46 | N/A |
| 52 Week Low | $4.60 | $10.75 |
| 52 Week High | $9.71 | $73.06 |
| Indicator | SRI | RNA |
|---|---|---|
| Relative Strength Index (RSI) | 52.55 | 31.24 |
| Support Level | $7.26 | N/A |
| Resistance Level | $7.51 | $14.30 |
| Average True Range (ATR) | 0.23 | 0.78 |
| MACD | 0.03 | -0.30 |
| Stochastic Oscillator | 71.01 | 3.02 |
Stoneridge Inc is a manufacturer of electrical and electronic components used in automotive vehicles. The company produces instrumentation systems, vehicle management electronics, application-specific switches and actuators, sensors, security alarms, and vehicle tracking devices and monitoring services for commercial, automotive, off-highway, and agricultural vehicle markets. The company has three reportable segments: Control Devices, Electronics, and Stoneridge Brazil. It generates the majority of its revenue from the Electronics segment that produces driver information systems, camera-based vision systems, connectivity, and compliance products, and electronic control units. Geographically, the company generates key revenue from the United States.
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.